Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H21NO2 |
Molecular Weight | 259.3434 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1
InChI
InChIKey=AQHHHDLHHXJYJD-UHFFFAOYSA-N
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
Molecular Formula | C16H21NO2 |
Molecular Weight | 259.3434 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:34:05 UTC 2023
by
admin
on
Fri Dec 15 16:34:05 UTC 2023
|
Record UNII |
9Y8NXQ24VQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC07AA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-ATC |
C07FA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
NDF-RT |
N0000175556
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
LIVERTOX |
NBK548218
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
266708
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1805
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-VATC |
QC07FA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-VATC |
QC07BA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
703319
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.2
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
NDF-RT |
N0000000161
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-ATC |
C07BA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-ATC |
C07FX01
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
475715
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
WHO-ATC |
C07AA05
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
||
|
FDA ORPHAN DRUG |
484315
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00571
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
564
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
8499
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
9Y8NXQ24VQ
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
100000092019
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
525-66-6
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
CHEMBL27
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
m9223
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | Merck Index | ||
|
9Y8NXQ24VQ
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
PROPRANOLOL
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
1940
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
235-867-6
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
ALTERNATIVE | |||
|
13013-17-7
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
SUPERSEDED | |||
|
4946
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
Propranolol
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
D011433
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
208-378-0
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
DTXSID6023525
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
C62073
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
2303
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
SUB10119MIG
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | |||
|
8787
Created by
admin on Fri Dec 15 16:34:05 UTC 2023 , Edited by admin on Fri Dec 15 16:34:05 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
ACTIVE ENANTIOMER->RACEMATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
In vitro studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6.
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
In vitro studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6. Side-chain oxidation is mediated mainly by CYP1A2 and to some extent by CYP2D6.
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma after chronic administration of parent drug.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||